Targeting the 4EBP1/HSP90β/Nrf2 Axis Sensitizes β-catenin-mutant Hepatocellular Carcinoma to mTOR Inhibitors via Ferroptosis Induction
The aberrant activation of the mTOR pathway and its crosstalk with other signaling cascades represent key drivers of hepatocellular carcinoma (HCC) progression. mTOR-mediated ferroptosis suppression has been implicated in HCC resistance to chemotherapy. This study aimed to elucidate the mechanisms underlying mTOR inhibitor resistance and to evaluate the therapeutic potential of multidrug combinations in β-catenin-mutant HCC.
Authors
- Runze Shang (ORCID: https://orcid.org/0000-0002-7958-0700)
- Deyu Fan
- Fule Deng
- Rong Li
- Gang Liu
- Yi Zhou
- Lanxuan Huang
- Zimu Wang
- Meng Xu
- Ning Wei
Publication Details
- Journal
- Journal of Clinical and Translational Hepatology
- Published
- 2026-06-16
- DOI
- https://doi.org/10.14218/jcth.2026.00072
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China